Franklin Schneider, MD
Cardiovascular Disease · Providence, RINPI 1497759294
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $5,991 of the $8,202 with a category attached, or 73.0%. 4 manufacturers reported payments, led by Edwards Lifesciences at 39.1% of the total. 2025 is the largest year on record at $3,779, more than ten times the $17 reported in 2021. Among cardiovascular disease clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $126.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$3K
- Abbott$3K
- Ancora Heart, Inc.$2K
- Boston Scientific$235
What the payments were for
- Travel & lodging$5,99173%
- Food & beverage$2,21227%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 34 | $3,208 |
| Abbott | 21 | $3,005 |
| Ancora Heart, Inc. | 6 | $1,754 |
| Boston Scientific | 4 | $235 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$2,095
- AccuCinch$1,754
- EVOQUE$1,342
- PASCAL$1,282
- AMPLATZER AMULET$337
- TRICLIP$122
- WATCHMAN FLX$117
How this compares
$8,202 in reported general payments places this provider in the 90th percentile of 86 cardiovascular disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 683 | $705,046 |
| XareltoRivaroxaban | 165 | $201,831 |
| EntrestoSacubitril/Valsartan | 98 | $120,716 |
| JardianceEmpagliflozin | 39 | $43,175 |
| Praluent PenAlirocumab | 63 | $38,230 |
| BrilintaTicagrelor | 31 | $23,437 |
| Repatha SureclickEvolocumab | 15 | $18,616 |
| Atorvastatin Calcium | 759 | $9,724 |
| Rosuvastatin Calcium | 374 | $8,427 |
| Metoprolol Succinate | 482 | $6,243 |
| Ezetimibe | 248 | $5,926 |
| Dofetilide | 27 | $5,309 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 173 | $4,967 |
| Carvedilol | 336 | $3,910 |
| Amiodarone Hcl | 99 | $3,583 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Providence
- Ara SadaniantzProvidence$27K
- John CavaProvidence$12K
- Jeremy LumProvidence$10K
- Gisele SalibaProvidence$7K
- Angie SeoProvidence$5K
- Sumbal JanjuaProvidence$3K
- Jack KlieProvidence$2K
- Gary KatzmanProvidence$2K
- Christina Al MaloufProvidence$2K
- Raad AlmuhaisenProvidence$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.